drugset / Trial / NCT05137548
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a single-center, open-label, 2-cohort, multiple dose, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with tenofovir disoproxil fumarate and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the investigational drug interacts with tenofovir disoproxil fumarate.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2021-12-23
- Completion
- 2021-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FOSCLEVUDINE ALAFENAMIDE | Other / unclassified | 50 mg | Oral |
| Subject | Tenofovir | Small molecule | 300 mg | Oral |
Indications
No indication recorded.